Earnings
Home›Earnings›Previews›Vericel, Xenia Hotels, and International Paper post ov…
Vericel, Xenia Hotels, and International Paper post overlooked Q2 wins
Vericel raised its 2026 revenue guidance to $330 million to $340 million and recorded Q2 revenues up 22% year over year, while Xenia Hotels and International Paper also reported positive developments.
Earnings season often highlights large-cap results, but MarketBeat Ratings points to three smaller companies that showed notable execution in recent quarters: Vericel in biotechnology, Xenia Hotels & Resorts in real estate, and International Paper in paper products. Vericel, a cell-therapy developer for regenerative medicine, saw shares rise more than 25% year to date despite a brief pullback after its Q2 2026 earnings release on July 30. The firm raised its full-year 2026 revenue guidance again, now to a range of $330 million to $340 million, attributing the outlook to higher forecasts for its cartilage product MACI. It also reported that its burn care business delivered strong momentum, with Q2 revenues up 22% year over year, driven by NexoBrid record revenue above $1.5 million.
Alongside the guidance increase, the outlet highlights Vericel’s solid quarterly fundamentals, including record revenue, GAAP net income of $2.2 million, and free cash flow that supported the company’s first-ever $200 million share repurchase program. Vericel is also pursuing marketing authorization for MACI in the U.K., a step described as part of geographic diversification.
For Xenia Hotels & Resorts, a REIT focused on premium hotels and luxury properties, MarketBeat Ratings says shares are up nearly 37% year to date, even after a dip following its latest earnings. The report notes that investors may have focused on headline top-line results, which it characterizes as difficult in the latest quarter, even as the company delivered other positives that were less widely discussed.